trim13 Antibody

What is TRIM13 and what are its key cellular functions?

TRIM13 (also known as RFP2, LEU5, RNF77) is an endoplasmic reticulum (ER) membrane-anchored E3 ubiquitin ligase with diverse cellular functions. It plays critical roles in ER-associated degradation (ERAD) of misfolded proteins, regulation of ER stress-induced autophagy, and modulation of innate immune responses via NF-κB signaling. TRIM13 enhances ionizing radiation-induced p53/TP53 stability and apoptosis by ubiquitinating MDM2 and AKT1, decreasing AKT1 kinase activity through proteasomal degradation . Recent research has identified TRIM13 as a regulator of cholesterol metabolism and a potential tumor suppressor in multiple cancer types .

What types of TRIM13 antibodies are available for research applications?

Researchers can utilize several types of TRIM13 antibodies, including rabbit polyclonal antibodies targeting full-length or specific regions (e.g., amino acids 1-350) and mouse polyclonal antibodies targeting the N-terminal region (amino acids 1-100) . These antibodies have been validated for various applications including Western blotting (WB) and immunohistochemistry on paraffin-embedded tissues (IHC-P). The choice between these antibodies depends on the specific experimental needs, with each offering different specificities and application compatibilities .

How can I validate TRIM13 antibody specificity for my experimental system?

Validation of TRIM13 antibody specificity requires a multi-faceted approach. First, perform Western blot analysis with positive controls such as HEK-293T or HeLa cell lysates, which should show the predicted band at approximately 47 kDa . Include negative controls through TRIM13 knockdown using siRNA or CRISPR/Cas9 techniques to confirm band specificity. For immunohistochemistry applications, compare staining patterns in tissues known to express TRIM13 (such as breast, brain, or vascular tissues) with appropriate isotype controls . Cross-validation using two different antibodies targeting distinct epitopes of TRIM13 can provide additional confidence in antibody specificity.

What are the optimal conditions for Western blot detection of TRIM13?

For optimal Western blot detection of TRIM13, use fresh cell or tissue lysates prepared with RIPA buffer supplemented with protease inhibitors and deubiquitinase inhibitors (N-ethylmaleimide). TRIM13 has a predicted band size of 47 kDa . Recommended antibody dilutions are typically 1:1000 for primary antibody incubation overnight at 4°C . Use 4-12% gradient gels for better resolution, and include positive controls such as HEK-293T or HeLa cell lysates. When studying TRIM13's role in ubiquitination, consider treating samples with proteasome inhibitors (e.g., MG132) prior to lysis to prevent degradation of ubiquitinated targets. Transfer efficiency can be enhanced using PVDF membranes with 0.2 μm pore size due to TRIM13's molecular weight properties.

How should I approach immunohistochemical detection of TRIM13 in tissue samples?

For successful immunohistochemical detection of TRIM13, paraffin-embedded tissues should undergo proper antigen retrieval, preferably using citrate buffer (pH 6.0) with heat-induced epitope retrieval. A 1:100 dilution of anti-TRIM13 antibody has been validated for human tissues including breast cancer and brain samples . Block endogenous peroxidase activity and use proper blocking solutions to minimize background staining. When studying atherosclerotic tissues, co-staining with markers for smooth muscle cells (SMMHC) or macrophages (CD68) can help identify cell-specific expression patterns of TRIM13 . For dual immunofluorescence applications, ensure secondary antibodies have minimal cross-reactivity and include appropriate controls to validate co-localization findings.

What approaches can be used to study TRIM13-mediated protein ubiquitination?

To investigate TRIM13-mediated ubiquitination, implement co-immunoprecipitation assays followed by immunoblotting with anti-ubiquitin antibodies. Cell extracts should be prepared after treatment with proteasome inhibitors (MG132, 10 μM for 4-6 hours) to prevent degradation of ubiquitinated proteins . For identifying specific ubiquitination sites and linkage types, mass spectrometry analysis of immunoprecipitated proteins can be performed. Proximity ligation assays (PLA) have proven effective for detecting TRIM13 interactions with potential substrates like SOCS1/3 in response to inflammatory stimuli . Expression of tagged ubiquitin constructs (HA-Ub, His-Ub) alongside TRIM13 can help distinguish between different ubiquitin chain topologies. Controls should include catalytically inactive TRIM13 mutants (RING domain mutations) to confirm E3 ligase dependency.

How does TRIM13 regulate cholesterol homeostasis and atherosclerosis development?

TRIM13 regulates cholesterol homeostasis through a dual mechanism affecting both cholesterol efflux and uptake. For cholesterol efflux, TRIM13 ubiquitinates liver X receptors (LXRα/β), targeting them for proteasomal degradation, which subsequently downregulates the expression of ATP-binding cassette transporters ABCA1 and ABCG1 . This inhibits cholesterol efflux from cells, particularly macrophages and vascular smooth muscle cells. For cholesterol uptake, TRIM13 ubiquitinates and degrades suppressor of cytokine signaling proteins (SOCS1/3), leading to enhanced STAT1 signaling and increased expression of the oxidized LDL receptor CD36 . These combined actions promote foam cell formation and atherosclerosis development. Studies using ApoE−/− mice on Western diet have demonstrated that TRIM13 expression is induced in the aorta and peritoneal macrophages, correlating with increased arterial lipid accumulation . Genetic deletion of TRIM13 protected against diet-induced atherosclerosis by preserving LXRα/β and SOCS1/3 levels, thereby maintaining proper cholesterol efflux and preventing excessive oxLDL uptake .

How do post-translational modifications affect TRIM13 activity and substrate specificity?

Post-translational modifications (PTMs) significantly influence TRIM13 activity and substrate specificity, though this remains an underexplored area. Research suggests that TRIM13's E3 ligase activity may be regulated through auto-ubiquitination, potentially creating a feedback mechanism that controls its own stability and function. TRIM13's substrate recognition appears to be influenced by inflammatory cytokines like IL-1β, which can induce TRIM13 expression and promote its interaction with targets such as LXRα/β and SOCS1/3 . The subcellular localization of TRIM13 at the ER membrane likely restricts its access to certain substrates, creating compartmentalized regulation. When studying TRIM13 PTMs, researchers should consider phosphorylation states that may alter binding affinities and employ phosphatase inhibitors during protein extraction. Mass spectrometry analysis of purified TRIM13 can help identify novel modification sites that may serve as regulatory switches controlling its E3 ligase activity toward different substrates in response to cellular stresses.

What are common challenges when detecting endogenous TRIM13 and how can they be addressed?

Detecting endogenous TRIM13 presents several challenges. First, TRIM13 is often expressed at relatively low levels in many cell types, requiring sensitive detection methods. Researchers should optimize protein extraction using specialized buffers containing deubiquitinase inhibitors and consider using enhanced chemiluminescence substrates for Western blot detection . Second, the membrane-bound nature of TRIM13 (ER-anchored) can complicate extraction, necessitating proper membrane solubilization with detergents like Triton X-100 or CHAPS. Third, potential cross-reactivity with other TRIM family members can be addressed by validating with TRIM13 knockout/knockdown controls and using antibodies targeting unique regions . For immunohistochemistry applications, background staining issues can be minimized through optimized blocking procedures and thorough washing steps. Finally, when studying TRIM13-mediated ubiquitination, the transient nature of this modification requires proteasome inhibition (MG132 treatment) before sample collection to stabilize ubiquitinated proteins .

How can I establish appropriate experimental models to study TRIM13 function?

Establishing appropriate experimental models for TRIM13 research requires careful consideration of cellular context and physiological relevance. For in vitro studies, choose cell lines with detectable endogenous TRIM13 expression (e.g., HEK-293T, HeLa, THP-1) or those relevant to specific pathologies (vascular smooth muscle cells for atherosclerosis, lung cancer cell lines for oncology research) . Generate stable TRIM13 knockout or knockdown models using CRISPR/Cas9 or shRNA approaches, complemented by rescue experiments with wild-type or mutant TRIM13 to confirm specificity. For inducible systems, doxycycline-regulated expression can help study dose-dependent effects while avoiding adaptive responses to constitutive expression. In vivo models should consider tissue-specific TRIM13 knockout mice or ApoE−/− backgrounds for atherosclerosis studies . For cancer research, patient-derived xenografts can better recapitulate tumor heterogeneity than cell line xenografts. Always include appropriate controls and validate TRIM13 expression levels across experimental conditions.

What controls are essential when studying TRIM13-mediated protein ubiquitination?

When investigating TRIM13-mediated ubiquitination, several essential controls must be implemented for result validation. First, include a catalytically inactive TRIM13 mutant (typically with RING domain mutations affecting zinc coordination) to confirm the E3 ligase activity dependency. Second, employ TRIM13 knockout/knockdown cells alongside wild-type controls to establish the specificity of the ubiquitination events. Third, use K48R and K63R ubiquitin mutants to distinguish between degradative (K48-linked) and non-degradative (K63-linked) ubiquitination . Fourth, include both proteasome inhibitors (MG132) and lysosome inhibitors (chloroquine, bafilomycin A1) to determine the degradation pathway of the ubiquitinated substrates. Fifth, perform sequential immunoprecipitation experiments (first for the substrate, then for ubiquitin) to confirm direct ubiquitination rather than associated ubiquitinated proteins. Finally, include time-course studies following stimulation (e.g., with IL-1β) to capture the dynamic nature of ubiquitination events, particularly for substrates like LXRα/β and SOCS1/3 .

How can TRIM13 be targeted therapeutically in atherosclerosis and cancer?

Therapeutic targeting of TRIM13 represents a promising approach for atherosclerosis and certain cancers, though different strategies are required for each condition. For atherosclerosis, inhibiting TRIM13's E3 ligase activity could preserve LXRα/β and SOCS1/3 levels, thereby promoting cholesterol efflux and preventing foam cell formation . Small molecule inhibitors targeting the RING domain or the substrate-binding interfaces could be developed using structure-based drug design. Alternatively, antisense oligonucleotides or siRNA-based approaches could downregulate TRIM13 expression specifically in vascular tissues or macrophages. For cancers where TRIM13 functions as a tumor suppressor (e.g., lung cancer), therapeutic strategies should aim to restore or enhance TRIM13 expression or activity . This could involve epigenetic modifiers to reverse silencing of the TRIM13 gene, stabilization of TRIM13 protein, or mimetics that target the same downstream pathways. Combination therapies targeting both TRIM13 and its effector pathways (NF-κB signaling, LXR activation) might provide synergistic benefits while minimizing potential side effects from complete TRIM13 inhibition or overactivation.

What emerging technologies can advance our understanding of TRIM13 function?

Emerging technologies offer unprecedented opportunities to elucidate TRIM13 function with greater precision. CRISPR-based screens (CRISPRa/CRISPRi) can systematically identify genes that modulate TRIM13 activity or its downstream effects. Proximity-dependent biotinylation approaches (BioID, TurboID) can map the TRIM13 interactome within the native cellular environment, potentially revealing novel substrates and regulatory partners. For structural insights, cryo-electron microscopy could determine the three-dimensional organization of TRIM13 complexes with substrates, guiding rational drug design. Single-cell technologies (scRNA-seq, CyTOF) can reveal cell type-specific functions of TRIM13 in heterogeneous tissues like atherosclerotic plaques or tumor microenvironments . Organoid models derived from patient samples can provide physiologically relevant systems to study TRIM13 in disease contexts. Finally, in vivo CRISPR-based genome editing combined with lineage tracing could elucidate the temporal and spatial requirements for TRIM13 during disease progression in animal models, informing the optimal timing and context for therapeutic intervention.

How do the ubiquitination targets of TRIM13 differ between cell types and disease states?

The ubiquitination targets of TRIM13 demonstrate remarkable context-dependency across different cell types and disease states, necessitating systematic comparative analyses. In atherosclerosis models, TRIM13 primarily targets LXRα/β and SOCS1/3 in both macrophages and vascular smooth muscle cells, but the relative importance of these targets may differ between cell types . For instance, LXRα/β regulation might be more critical in macrophages for cholesterol efflux, while SOCS1/3 degradation could have greater impact in smooth muscle cells. In cancer contexts, TRIM13 targets RPS27A in lung cancer cells, affecting NF-κB signaling and tumor progression . Different ubiquitination patterns (K48 versus K63-linked chains) may predominate depending on cellular context, controlling whether targets undergo degradation or functional modification. To investigate these differences, researchers should implement parallel proteomic approaches in relevant cell types, including proximity labeling combined with mass spectrometry under normal and disease conditions. Validation studies should include cell type-specific conditional knockout models and rescue experiments with substrate-binding mutants of TRIM13 to establish the relative contribution of different targets to disease phenotypes.

Table 1: TRIM13 Expression Patterns in Different Tissues and Disease States

Table 2: Validated TRIM13 Ubiquitination Targets and Their Functional Outcomes

Table 3: TRIM13 Antibody Applications and Validation Parameters